Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2019

Open Access 01-12-2019 | Mood Disorders | Research

Low empowerment and diabetes regimen distress are related to HbA1c in low income type 1 diabetes patients in a Brazilian tertiary public hospital

Authors: M. S. V. M. Silveira, A. Moura Neto, A. C. Sposito, L. Siminerio, E. J. Pavin

Published in: Diabetology & Metabolic Syndrome | Issue 1/2019

Login to get access

Abstract

Background

Adults with type 1 diabetes (T1D) have a high risk of developing depressive symptoms and diabetes-related distress (DD). Low socioeconomic level is associated with increased risk of poor self-management, treatment difficulties and psychological distress. The goals of this study were to document the frequency of major depressive disorder (MDD), high depressive symptoms and high DD, to assess levels of empowerment and to determine the association with each of these measures and glycemic control in a low-income Brazilian sample of adults with T1D.

Methods

In a cross-sectional study, inclusion criteria were age > 18 years and diagnosis of T1D > 6 months. Exclusion criteria were cognitive impairment, history of major psychiatric disorders, severe diabetes-related complications and pregnancy. Diagnoses of MDD were made using interview-based DSM-5 criteria. Depressive symptoms were evaluated by the depression subscale of the Hospital Anxiety and Depression Scale (HAD-D). The Diabetes Distress Scale (DDS) assessed DD. Empowerment levels were evaluated by the Diabetes Empowerment Scale short form (DES-SF). Glycemic control was measured by HbA1c. The latest lipid panel results were recorded. Number of complications was obtained from medical records.

Results

Of the 63 T1D patients recruited, 36.5% were male, mean age was 31.5 (± 8.9), mean number of complications was 1 (± 1.1), and mean HbA1c was 10.0% (± 2). Frequency of MDD was 34.9% and 34.9% reported high depressive symptoms. Fifty-seven percent reported clinically meaningful DD. High diabetes regimen distress and low empowerment were associated to HbA1c (p = 0.003; p = 0.01, respectively). In multivariate analyses, lower empowerment levels were associated to higher HbA1c (beta − 1.11; r-partial 0.09; p value 0.0126). MDD and depressive symptoms were not significantly correlated with HbA1c in this expected direction (p = 0.72; p = 0.97, respectively).

Conclusions

This study showed high rates of MDD, high depressive symptoms and high DD and low levels of empowerment in this low income population. Empowerment and diabetes regimen distress were linked to glycemic control. The results emphasize the need to incorporate the psychological and psychosocial side of diabetes into strategies of care and education for T1D patients.
Literature
1.
Trief PM, Xing D, Foster NC, Maahs DM, Kittelsrud JM, Olson BA, Young LA, Peters AL, Bergenstal RM, Miller KM, Beck RW, Weinstock RS, T1D Exchange Clinic Network. Depression in adults in the T1D Exchange Clinic Registry. Diabetes Care. 2014;37(6):1563–72.PubMedCrossRef
2.
Berge LI, Øivind Hundal TR, Ødegaard KJ, Dilsaver S, Lund A. Prevalence and characteristics of depressive disorders in type 1 diabetes. BMC Res Notes. 2013;6:543.PubMedPubMedCentralCrossRef
3.
Barnard KD, Skinner TC, Peveler R. The prevalence of co-morbid depression in adults with type 1 diabetes: systematic literature review. Diabet Med. 2006;23(4):445–8.PubMedCrossRef
4.
Strandberg RB, Grave M, Wentzel-Larsen T, Peyrot M, Rokne B. Relationships of diabetes-specific emotional distress, depression, anxiety and overall well-being with HbA1c in adult persons with type 1 diabetes. J Psychosom Res. 2014;77:174–9.PubMedCrossRef
5.
Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069–78.PubMedCrossRef
6.
7.
Diretrizes da Sociedade Brasileira de Diabetes. 2015–2016; 62–8.
8.
American Diabetes Association. 4. Lifestyle management: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Supplement 1):S38–50.CrossRef
9.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes melittus. N Engl J Med. 2003;329:977–85.
10.
Berntein CM, Stockwell MS, Gallagher MP, Rosenthal SL, Soren K. Mental health issues in adolescents and young adults with type 1 diabetes. Prevalence and impact on glycemic control. Clin Pediatr. 2013;52(1):10–5.CrossRef
11.
Peyrot M. Levels and risks of depression and anxiety symptomatology among diabetic adults. Diabetes Care. 1997;20:585–90.PubMedCrossRef
12.
Gomes MB, de Mattos Matheus AS, Calliari LE, Luescher JL, Manna TD, Savoldelli RD, Cobas RA, Coelho WS, Tschiedel B, Ramos AJ, Fonseca RM, Araujo NB, Almeida HG, Melo NH, Jezini DL, Negrato CA. Economic status and clinical care in young type 1 diabetes patients: a nationwide multicenter study in Brazil. Acta Diabetol. 2013;50(5):743–52. https://​doi.​org/​10.​1007/​s00592-012-0404-3.PubMedCrossRef
13.
14.
15.
Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial care for people with diabetes: a position statement of the American diabetes association. Diabetes Care. 2016;39(12):2126–40.PubMedPubMedCentralCrossRef
16.
Rossi MC, Lucisano G, Funnell M, Pintaudi B, Bulotta A, Gentile S, Scardapane M, Skovlund SE, Vespasiani G, Nicolucci A, BENCH-D Study Group. Interplay among patient empowerment and clinical and person-centered outcomes in type 2 diabetes. The BENCH-D study. Patient Educ Couns. 2015;98(9):1142–9.PubMedCrossRef
17.
Skovlund SE, Peyrot M, DAWN International Advisory Panel. The diabetes attitudes, wishes and needs (DAWN) program: a new approach to improving outcomes of diabetes care. Diabetes Spectr. 2005;18(3):136–42.CrossRef
18.
Nicolucci A, Kovacs Burns K, Holt RIG, Comaschi M, Hermans N, Ishi H, Kokoszka A, Pouwer F, Skovlund SE, Stuckey H, Tarkun I, Vallis M, Wens J, Peyrot M, on behalf of the DAWN2 study group. Diabetes attitudes, wishes and needs second study (DAWN 2): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. Diabet Med. 2013;30(7):767–77.PubMedCrossRef
19.
Funnell MM, Anderson RM. Empowerment and self-management education. Clin Diabetes. 2004;22(3):123–7.CrossRef
20.
Funnel MM, Anderson RM, Arnold MS, et al. Empowerment: an idea whose time has come in diabetes education. Diabetes Educ. 1991;17(1):37–41.CrossRef
21.
Funnel MM, Anderson RM. Patient empowerment: a look ahead. Diabetes Educ. 2003;29(3):454–564.CrossRef
22.
Anderson RM, Funnell MM. The art of empowerment: stories and strategies for diabetes educators. 2nd ed. Alexandra: American Diabetes Association; 2005.
23.
Anderson B, Funnel MM, Tang TS. Self-management of health. In: Mensing C, editor. The art and science of diabetes self-management education. Chicago: American Association of Diabetes Educators; 2006. p. 43–6.
24.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). Arlington: American Psychiatric Association; 2013.CrossRef
25.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.PubMedCrossRef
26.
Botega NJ, Bio MR, Zomignani MA, Garcia C Jr, Pereira WA. Transtornos de humor em enfermarias de clínica médica e validação de escala de medida (HAD) de ansiedade e depressão. Revista de Saúde Pública. 1995;29:355–63.PubMedCrossRef
27.
Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res. 2002;52(2):69–77.PubMedCrossRef
28.
29.
Fisher L, Hessler DM, Polonsky WH, Mullan J. When is diabetes distress clinically meaningful? Establishing cut points for the diabetes distress scale. Diabetes Care. 2012;35(2):259–64.PubMedPubMedCentralCrossRef
30.
Curcio R, Alexandre NMC, Carvalho H, Lima MHM. Translation and adaptation of the diabetes distress scale-DDS in Brazilian culture. Acta paul enferm. 2012;25(5):762–7.CrossRef
31.
Anderson RM, Fitzgerald JT, Gruppen LD, Funnell MM, Oh MS. The diabetes empowerment scale-short form (DES-SF). Diabetes Care. 2003;26:1641–3.PubMedCrossRef
32.
33.
Anderson RM, Funnell MM, Fitzgerald JT, Marrero DG. The diabetes empowerment scale: a measure of psychosocial self-efficacy. Diabetes Care. 2000;23:739–43.PubMedCrossRef
34.
35.
Fisher L, Mullan JT, Aren P, Glasgow RE, Hessler D, Masharani V. Diabetes distress but not clinical depression or depressive symptoms is associated with glycaemic control in both cross-sectional and longitudinal analyses. Diabetes Care. 2010;33(1):23–8.PubMedCrossRef
36.
Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control—a meta analytic review of the literature. Diabetes Care. 2000;23:934–42.PubMedCrossRef
37.
Lustman PJ, Clouse REJ. Depression in diabetic patients: the relationship between mood and glycemic control. Diabetes Complicat. 2005;19(2):113–22.
38.
Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000;60:3278–85.CrossRef
39.
40.
41.
42.
Vest BM, Kahn LS, Danzo A, Tumiel-Berhalter L, Schuster RC, Karl R, Taylor R, Glaser K, Danakas A, Fox CH. Diabetes self-management in a low-income population: impacts of social support and relationships with the health care system. Chronic Illn. 2013;9(2):145–55.PubMedPubMedCentralCrossRef
43.
Gomes MB, Rodacki M, Pavin EJ, Cobas RA, Felicio JS, Zajdenverg L, Negrato CA. The impact of ethnicity, educational and economic status on the prescription of insulin therapeutic regimens and on glycemic control in patients with type 1 diabetes. A nationwide study in Brazil. Diabetes Res Clin Pract. 2017;134:44–52.PubMedCrossRef
44.
Joensen LE, Filges T, Willaing I. Patient perspectives on peer support for adults with type 1 diabetes: a need for diabetes-specific social capital. Patient Prefer Adherence. 2016;10:1443–51.PubMedPubMedCentralCrossRef
45.
Wingate LM, Graffy J, Holman D, Simmons D. Can peer support be cost saving? An economic evaluation of RAPSID: a randomized controlled trial of peer support in diabetes compared to usual care alone in East of England communities. BMJ Open Diabetes Res Care. 2017;5(1):e000328.PubMedPubMedCentralCrossRef
46.
Tang TS, Funnell M, Sinco B, Piatt G, Palmisano G, Spencer MS, Kieffer EC, Heisler M. Comparative effectiveness of peer leaders and community health workers in diabetes self-management support: results of a randomized controlled trial. Diabetes Care. 2014;37:1525–34.PubMedPubMedCentralCrossRef
47.
Tang TS, Funnell M, Gillard M, Nwankwo R, Heisler M. Training peers to provide ongoing diabetes self-management support (DSMS): results from a pilot study. Patient Educ Couns. 2011;85:160–8.PubMedPubMedCentralCrossRef
48.
Lopez PM, Islam N, Feinberg A, Myers C, Seidl L, Drackett E, Riley L, Mata A, Pinzon J, Benjamin E, Wyka K, Dannefer R, Lopez J, Trinh-Shevrin C, Maybank KA, Thorpe LE. A place-based community health worker program: feasibility and early outcomes, New York City, 2015. Am J Prev Med. 2017;52(3 Suppl 3):S284–9.PubMedPubMedCentralCrossRef
49.
50.
Metadata
Title
Low empowerment and diabetes regimen distress are related to HbA1c in low income type 1 diabetes patients in a Brazilian tertiary public hospital
Authors
M. S. V. M. Silveira
A. Moura Neto
A. C. Sposito
L. Siminerio
E. J. Pavin
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2019
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-019-0404-3

Other articles of this Issue 1/2019

Diabetology & Metabolic Syndrome 1/2019 Go to the issue

Research

Comparison of various steady state surrogate insulin resistance indices in diagnosing metabolic syndrome

Research

Multiple poor sleep characteristics and metabolic abnormalities consistent with metabolic syndrome among white, black, and Hispanic/Latina women: modification by menopausal status

Short report

Metformin paradoxically worsens insulin resistance in SHORT syndrome

Research

Oxidative stress and adipokine levels were significantly correlated in diabetic patients with hyperglycemic crises

Review

Smoking and diabetes: dangerous liaisons and confusing relationships

Research

Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in young patients with congenital generalized lipodystrophy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits